摘要
目的观察玻璃体腔内注射雷珠单抗联合复合式小梁切除术治疗新生血管性青光眼的临床疗效。方法新生血管性青光眼患者38例(38眼),随机分为治疗组和对照组,各19例(19眼)。治疗组先行玻璃体注射雷珠单抗0.05 m L(0.5 mg),于注射后4~7 d行复合式小梁切除术;对照组行睫状体冷凝术。观察手术后疗效。结果治疗组手术前后眼压分别为(6.5±1.7),(2.1±1.2)k Pa(P<0.01)。对照组手术前后眼压分别为(6.7±1.9),(2.5±1.2)k Pa(P=0.01)。治疗组手术后眼压低于对照组(P<0.05)。治疗组手术安全性及手术后视力恢复均优于对照组。结论玻璃体腔内注射雷珠单抗联合复合式小梁切除术治疗新生血管性青光眼安全有效,有较大的临床应用价值。
Objective To investigate the clinical efficacy of intravitreal ranibizumab injection combined with complex trabeculectomy in treatment of neovascular glaucoma.Methods Totally 38 patients(38 eyes) of neovascular glaucoma were divided into two groups of 19 cases in each randomly.Patients in treatment group were treateded with complex trabeculectomy after intravitreal injection 0.05 m L(0.5 mg) ranibizumab 4-7 days.Patients in control group were treateded with cyclocryotherapy.Visual acuity,intraocular pressure,iris neovascularization and complications were observed.Results The average intraocular pressure of preoperation and postoperation 1 month in treatment group were(6.5± 1.7) k Pa and(2.1± 1.2)k Pa.The difference of intraocular pressure before and after operation was significant.The average preoperative and postoperative intraocular pressure in control group were(6.7±1.9) k Pa and(2.5±1.2) k Pa.The postoprative intraocular pressure of treatment group was lower than that of control group,the difference was statistically significant(P < 0.05).Visual acuity and operative reaction after operation in treatment group were superior to those in control group.Conclusion Intravitreal injection of ranibizumab combined with complex trabeculectomy in treatment of neovascular glaucoma is safe and effective and worth in clinical application.
出处
《医药导报》
CAS
2016年第9期975-977,共3页
Herald of Medicine
基金
武汉市卫生和计划生育委员会基金资助项目(WX14B05)
